-Effective interstitial transport of particles is necessary for injected drug/diagnostic agents to reach the intended target; however, quantitative methods to estimate such transport parameters are lacking. In this study, we develop an in vivo model for evaluating interstitial convection of injected macromolecules and nanoparticles. Fluorescently labeled macromolecules and particles are coinfused with a reference solute at constant infusion pressure intradermally into the mouse tail tip, and their relative convection coefficients are determined from spatial and temporal interstitial concentration profiles. Quantifying relative solute velocity with a coinfused reference solute eliminates the need to estimate interstitial fluid velocity profiles, greatly reducing experimental variability. To demonstrate sensitivity and usefulness of this model, we compare the effects of size (dextrans of 3, 40, 71, and 2,000 kDa and 40-nm diameter particles), shape (linear dextran 71 kDa vs. 69 kDa globular protein albumin), and charge (anionic vs. neutral dextran 3 kDa) on interstitial convection. We find significant differences in interstitial transport rates between each of these molecules and confirm expected transport phenomena, testifying to sensitivity of the model in comparing solutes of different size, shape, and charge. Our data show that size exclusion (within a specific size range) dominates molecular convection, while mechanical hindrance slows larger molecules and nanoparticles; proteins convect slower than linear molecules of equal molecular mass, and negative surface charges increase convection through matrix repulsion. Our in vivo model is presumably a sensitive and reliable tool for evaluating and optimizing potential drug/diagnostic vehicles that utilize interstitial and lymphatic delivery routes. drug delivery; size exclusion; lymphatic uptake; extracellular matrix; subcutaneous AN EASY AND RELIABLE METHOD of measuring interstitial convection of macromolecules and nanoparticles is essential for optimizing the delivery of protein drugs, lymph node imaging agents, and injectable drug and cell carrier systems that utilize subcutaneous injection as a primary delivery route. Such injections induce interstitial fluid flow locally, which leads to solute convection that typically dominates diffusion as the primary transport mechanism for these larger solutes and particles. The emergence of drug delivery systems (i.e., nanoparticles and liposomes) that utilize interstitial and lymphatic transport necessitates a further characterization of transport in the interstitium (15-17). Despite its importance, a method to readily evaluate the convective transport parameters of interstitially injected macromolecules or nanoparticles is lacking.
AN EASY AND RELIABLE METHOD of measuring interstitial convection of macromolecules and nanoparticles is essential for optimizing the delivery of protein drugs, lymph node imaging agents, and injectable drug and cell carrier systems that utilize subcutaneous injection as a primary delivery route. Such injections induce interstitial fluid flow locally, which leads to solute convection that typically dominates diffusion as the primary transport mechanism for these larger solutes and particles. The emergence of drug delivery systems (i.e., nanoparticles and liposomes) that utilize interstitial and lymphatic transport necessitates a further characterization of transport in the interstitium (15) (16) (17) . Despite its importance, a method to readily evaluate the convective transport parameters of interstitially injected macromolecules or nanoparticles is lacking.
Factors such as size, shape, charge, and hydrophobicity influence the interstitial transport of macromolecules and nanoparticles, along with the complex microarchitecture of the extracellular matrix (ECM). Composed of fluid, solutes, fibrillar and bound proteins, and proteoglycans, the physical properties of the interstitial space are similar to those of a gel, and two-phase models where interstitial fluid is either free or bound are typically used to describe fluid and solute exchange in the interstitial space (5, 21, 22, 24, 25) . Such models of interstitial protein transport typically consider the solutes as a single phase in examining their effects on fluid transport and thus do not attempt to describe differences in the transport between different solutes; moreover, such theoretical models are difficult to test experimentally in living tissue, and most experimental models of interstitial solute convection have been performed in very well-defined in vitro systems rather than in vivo. For example, Johnston and Deen (11, 12) investigated convection of various proteins through agarose gels, which have a porous microstructure similar to that of the interstitium and demonstrated that molecular size dominates the convective differences there. Only a few measurements of local interstitial convection have been achieved (3) , including the work of Chary and Jain (8) , who first directly measured albumin convection by fluorescence recovery after photobleaching in normal and neoplastic tissues; this technique is more commonly used to measure protein or macromolecular diffusion in vivo (1, 4, 7, 14) .
Here we describe a new in vivo model that can directly compare the interstitial convection rates of two different solutes from the same infusion in living skin, minimizing experimental variability and thus providing a tool for optimizing interstitially injected drug vehicles and imaging agents. It expands on a previous model in mouse tail skin 1 that was developed to analyze fluid velocity in the superficial lymphatic network (3, 19, 20) . Our data demonstrate the sensitivity of the model, as macromolecules and nanoparticles differing in size, shape, and charge can be differentiated with respect to their convective transport parameters; additionally known interstitial transport phenomena are further validated by the model. Of course, molecular transport behavior may be different within different tissues, since the composition and architecture, degree of hydration, degree of vascularization and lymphatic drainage, and fixed charge density of the ECM vary not only among different tissues but can also vary within the same tissue according to diet, age, etc. However, because our model relies on the differential transport behavior between two coinjected molecules, it can eliminate some of this variability and indeed may prove useful for characterizing some of these differences. This model thus exhibits sensitivity, usefulness, and reliability in evaluating and optimizing interstitial transport of potential drug vehicles and diagnostic agents that are delivered interstitially (e.g., by subcutaneous injection). Average relative solute velocity ratio
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MATERIALS AND METHODS
Experimental setup. This study utilized a total of 18 female 6-wkold mice that weighed between 20 and 30 g. All protocols were approved by the Animal Care and Use Committees of Northwestern University and Massachusetts General Hospital. Anesthesia was performed by subcutaneous injection of ketamine hydrochloride at 10 mg/kg body wt (Ketalar, Parke-Davis, Morris Plains, NY) and xylazine at 1 mg/kg (Rompun, Haver Mobay, Shawnee, KS). The tail was gently washed, and the mouse was placed on a small plate in the supine position and its tail immobilized from underneath with tape. A small heating pad was used to maintain body temperature throughout the experiment.
Infusions were accomplished using a setup described earlier (20) as shown in Fig. 1A . The injectate (a solution of fluorescently labeled macromolecules) was drawn into a catheter, which was connected to a pressure head of 33 mmHg. A 30-gauge infusion needle was inserted intradermally, in a proximal direction parallel to the tail axis, ϳ1 mm into the tail tip. At the beginning of each experiment (time t ϭ 0), the stopcock was opened, creating a step change in pressure at the tip from physiological baseline interstitial fluid pressure [normally ϳ9 Fig. 1 . A: schematic of the experimental setup where P represents a fixed pressure head of 33 mmHg. At time t ϭ 0, the infusion starts, the flow rate is monitored with a bubble in the infusion line, and the injectate is deposited interstitially. Images are captured from an epifluorescence microscope with a charge-coupled device camera (CCD). B and C: fluorescence intensity profiles from a typical coinfusion. B: images of the interstitium, taken a few seconds apart, following a coinfusion of 71-kDa dextran (71k-Dx; green)/3-kDa dextran (3k-Dx; red) show that the 71k-Dx has moved further within the interstitium, and more efficiently into the lymphatics, than the 3k-Dx. The infusion site is upstream from the left edge of the image. C: average intensity profiles corresponding to the images in A. mmHg (20) ] to the reservoir pressure and thereby initiating infusion into the tail. The rate of fluid introduced (monitored with a bubble far upstream in the tubing) averaged 0.1 l/min into ϳ20 mm 3 of tissue, or ϳ5 l ⅐ g Ϫ1 ⅐ min Ϫ1 (yielding maximal interstitial fluid velocities on the scale of 50 m/min) and did not result in visible swelling, and edema was avoided by normal drainage into lymphatics.
Injectate. Each experimental test molecule, with a FITC-label (green), was coinfused with a Texas red-labeled reference molecule, 3-kDa dextran (3k-Dx). In this way, experimental variation could be minimized; since their interstitial distribution patterns are driven by a single fluid flow profile, spatial and temporal differences between the test and reference distribution profile reflect only their differences in convective transport parameters (and uptake into the lymphatic and blood vasculature; see APPENDIX for explanation). We evaluated the relative convection rates of the following five molecules: dextrans of 2,000 kDa (2M-Dx), 40 kDa (40k-Dx), and 71 kDa (71k-Dx); anionic dextran of 3 kDa (3k-An-Dx); and bovine serum albumin (69k-BSA) (all from Sigma-Aldrich, St. Louis, MO). The first three served to compare the effects of molecular mass using uncharged, linear molecules, while the anionic dextran was tested for effects of charge alone (since it was the same size as the reference molecule). The albumin was used to test the effects of both size and charge as, at 69 kDa, it is nearly the same molecular mass as 71k-Dx but is a folded protein with nonuniform charge distribution rather than a linear uncharged molecule; thus the radius of albumin was measured to be ϳ60% that of 71k-Dx (9) . We also evaluated a spherical particle for relevance to drug delivery vehicles: yellow-green fluorescent carboxylate modified polystyrene nanospheres (FluoSpheres, Molecular Probes, Eugene, OR) with a mean diameter of 40 nm. The injectate was composed of 10 mg/ml of each solute in phosphate-buffered saline.
Image acquisition. Fluorescence images of the tail interstitium were recorded with an epifluorescence microscope (Zeiss, Germany) and a high-performance charge-coupled device camera system (SenSys, Photometrics, Tuscon, AZ) described earlier (20) . Two fluorescence channels (Omega Optical, Brattleboro, VT), consisting of fluorescein and rhodamine filters were used to measure fluorescence from the FITC-and Texas red-labeled solutes, respectively, with no signal overlap detected between the two fluorophores. In addition, a linear range of concentration intensity was verified in flat capillary tubes of 300-m inner diameter (Vitrocom), which is approximately the thickness of the skin in the tail. Although this does not verify that the same concentration-intensity relationship will exist in tail skin, it does support the validity of the assumption of concentration-intensity linearity in tail skin since 1) the tissue thickness is approximately constant throughout the measurement region (verified histologically), and 2) the maximum intensity measured is within the linear range. Images were taken at four to seven consecutive windows moving proximally along the tail from the site of infusion (the exact position of x ϭ 0 was arbitrary; see Theory). The background intensity was taken just before beginning the infusion, and images were captured every 2-8 min at fixed exposure. In most cases, only four consecutive windows were needed to capture the full concentration profile. Figure 1B shows a typical image of the mouse tail under green and red fluorescence at approximately the same time (10 min, with 2 s between them) from a coinfusion of 71k-Dx/3k-Dx, demonstrating their relative concentration profiles. In this case, the larger molecule (71k-Dx in green) had traveled, on average, further than the smaller reference solute (3k-Dx in red); the analysis of such concentration profiles is addressed in the next section.
Data analysis. The diameter of the infusion needle is relatively large with respect to the tip of the mouse tail where the infusion is made; this effectively makes the fluid transport problem one-dimensional (changes only in the axial direction), since the entire tip of the tail is uniformly infused. Therefore, we considered only the axial convective transport of fluid and solute, because fluid pressure gradients, and thus convective transport, in the radial direction were negligible in comparison (20) . Each image of the tail, 3 mm wide, was divided into 60 vertical subregions (27 pixels or 0.05 mm wide), such that intensity was averaged over the height of the tail but in very small increments in the direction of flow. In this way, a virtually continuous axial concentration profile could be measured at each time point. Intensity histograms were created using Metamorph software (Universal Imaging, Downington, PA). Figure 1C shows the average intensity vs. distance profile for the corresponding image in Fig. 1B . The average intensity decreases over distance, since the concentration of the solute is at its maximum value at the site of infusion (x ϭ 0). Figure 2 shows average intensity vs. distance profile at different time points across the tail interstitium, and mean intensities I were normalized to :
where I min is the initial background intensity and Imax is the intensity of the injectate (e.g., I at x ϭ 0). Again, we assumed that the intensity was linearly related to the solute concentration such that the normalized intensity was equivalent to the normalized concentration.
THEORY
This study addresses convective transport of injected solute through the interstitium, and thus diffusion was not considered as a contributing transport mechanism; only the regions with large Peclet numbers (e.g., high ratio of convective to diffusive transport for a given solute and fluid velocity) were evaluated. We verified a posteriori that, for the smallest molecule used, 3k-Dx, Peclet number ϳ 100 at 2 cm from the infusion site and well within our measurement region; thus diffusive transport of the fluorescent solutes was neglected in this region.
Several factors affect the solute convection velocity through the tissue interstitium: properties of the solute, such as size, charge, and hydrophobicity; properties of the interstitial matrix, such as porosity and fixed charge density; and the fluid velocity, which provides the driving force for convection and depends on the infusion pressure and the hydraulic resistance of the tissue. For very small solutes having no interactions with the matrix, the average solute velocity will closely approximate the average fluid velocity (u i Х v). Larger molecules may be restricted to a smaller fraction of the pores (e.g., only to the larger pores with higher average fluid velocities), leading to an average solute velocity that is higher than the average fluid velocity (u i Ͼ v), such as seen in size exclusion chromatography (6) . On the other hand, large molecules may also interact with the ECM, either by mechanical hindrance or charge interactions, which could lead to an apparent solute drag and result in a lower average solute velocity than that of the fluid (u i Ͻ v). For proteins and particles whose sizes are on the order of 1-50 nm, one would expect a combination of these effects. Our aims here were not to theoretically evaluate each of these complex interactions, but instead to simply measure and compare the average convective velocities for a variety of molecules. The fact that we coinjected meant the fluid velocity was the same for two molecules, and therefore their solute velocities could be directly compared. A measure of net solute velocity is the most relevant information needed to compare and optimize interstitial transport of an injected large molecule, particle, or drug carrier. Thus our measurement of net solute velocity relative to that of a reference molecule eliminates the need to accurately determine fluid velocity (which decreases with distance from the infusion) and reduces experimental variability. The relative solute velocity ratio also reflects the relative lymphatic uptake efficiency, since the interstitium poses a greater barrier to lymphatic uptake than the lymphatic vessels (18) .
The Darcy scale axial fluid velocity v in the mouse tail skin following an interstitial infusion has been previously shown to decay exponentially with distance at steady state (20) :
where ␤ is the effective lymphatic conductance (s Ϫ1 ⅐mmHg Ϫ1 ), K is the effective hydraulic conductivity (mm 2 ⅐s Ϫ1 ⅐mmHg Ϫ1 ), P o is the interstitial fluid pressure (mmHg) in the tissue (above baseline, due to the injection), and ␣ ϭ (K/␤) 1/2 is the ratio of interstitial to lymphatic conductance. Each of these depends only on the specifics of the tissue and injection; thus they may differ between animals but will be the same relative to each coinjected solute.
We assumed that the mean velocity of solute i, u i , is linearly related to the mean fluid velocity, according to a convection coefficient i ,
The assumption that fluid and solute velocities are linearly related is valid only within the convection-dominated transport region, and only within a region where tissue fluid volume fraction is relatively constant, as is the case within our measurement region (for further validation, see Ref. 20) . In the case of a very small solute (relative to interstitial pore size), one can expect the solute velocity to approach the fluid velocity ( i Х 1). When the solute is coinjected with a reference solute r, the ratio of their velocities will equal the ratio of their convection coefficients, since v is the same for each. The term ␥ i is introduced as the ratio of the convection coefficient of solute i with that of the reference solute r, which can thus be directly measured from their relative convection profiles without knowing the fluid velocity profile:
To determine ␥ i , we considered that
where x i is the mean distance convected by solute i at time t. Note that this assumes that the only contributing factor to the movement of the solute is fluid convection; in other words, the partitioning of solute from fluid uptake into blood and lymphatic capillaries is small compared with convective transport, and this assumption is explained in the APPENDIX. Upon integration, a logarithmically decaying relationship between x i and t is seen:
The constant ϭ ␤P o depends only on fluid parameters. Furthermore, the moving front of the solute is diffuse, so x i ϭ x i can be determined as a concentration-weighted average distance (i.e., by calculating the mean residence distance, x i ) at any time point according to:
This results in a new data set of x i vs. t for each of the test and reference solutes; Fig. 3 illustrates such a data set. Data fitting. With the curves of x i vs. t for each solute, the velocity profiles of each were determined by their local derivatives, u i ϭ ‫ץ‬x i /‫ץ‬t, allowing the average relative solute velocity Fig. 3 . Typical mean residence distance vs. time (x vs. t) curve from a 2,000-kDa dextran (2M-Dx; E) and 3k-Dx (ϩ) coinfusion. As expected, x (the distance of the moving front) increases with time, since the solutes are being continuously infused at a constant pressure. Also shown are the lines that are fit for 2M-Dx (dashed line) and 3k-Dx (solid line) by nonlinear regression. From these figures, a new data set of x vs. t for each particle is generated. With this data set, the difference line (xxx) is calculated (which is fit to Eq. 9 through nonlinear regression).
ratio ␥ i to be determined. Considering again Eq. 6, the reference and test curves of x i vs. t are described by
and
The values of x i o and x r o represent the true site of injection (x ϭ 0) for the test and reference solutes, which are extrapolated from the intensity profiles (note that the exact deposit site is unknown during the experiment).
Since ␣ depends only on the fluid and not the solutes, Eqs. 8a and 8b can be collapsed into a single data set (note that x i o and x r o are equal to each other and therefore cancel out):
The original data did not contain identical time points for each of the coinjected solutes (i.e., they were seconds apart since two fluorescent channels could not be recorded simultaneously), so a new data set, the difference line (x i Ϫ x r ), was generated from the best fits of each of the individual solute profiles (Eqs. 8a and 8b) using NLREG software (Phillip Sherrod, Brentwood, TN). This new data set was then fit to Eq. 9, enabling the ratio of the new fitted values of i and r , or the average relative test solute velocity ␥ i , to be determined. Figure  3 shows a plot of a typical x vs. t curve (from an injection of 2M-Dx and 3k-Dx as a reference), including the difference line, which was fit to Eq. 9 through nonlinear regression to determine ␥ i .
RESULTS
Average relative solute velocity ratios. Table 1 compares the average relative velocity ratio and size for each of the test solutes. Radii were estimated as follows: for dextrans, using the formula r ϭ 0.305M 0.47 (where M ϭ molecular mass) of Leypoldt and Henderson (13) and for albumin, from Garlick and Renkin (9) . The average nanosphere radius was determined by the manufacturer to be 20 nm. Figure 4 compares the mean ␥ i values for each of the test particles.
For the three dextrans used to make size comparisons (2M, 71k, and 40k-Dx), 71k had the highest ␥ i , and statistical significance was verified through one-way ANOVA of fixedeffects model (P ϭ 0.026). A one-tailed Student's t-test confirmed that ␥ i for 71k-Dx was statistically greater than that of the folded protein of similar molecular mass, 69k-BSA (P ϭ 0.031), and a two-tailed Student's t-test verified that ␥ i for 3k-An-Dx was significantly different than unity (the theoretical ␥ i value for the standard neutral 3k-Dx; P ϭ 0.039). All of the test solutes, except the nanospheres, displayed higher relative velocities than the reference molecule, 3k-Dx. The nanospheres showed the lowest ␥ i value and was the only test particle that convected slower than the reference particle.
The statistically significant differences of ␥ i for the various comparisons mentioned above demonstrate the sensitivity of this model. Additionally, the known and expected convective transport phenomena in the interstitium, such as the effects of size, shape, and charge, were statistically verified by this model, therefore further testifying to its sensitivity.
DISCUSSION
This study illustrates a new experimental tool for estimating interstitial convective properties of injected macromolecules and particles by coinfusion with a reference molecule into mouse tail skin and determining their relative interstitial velocity profiles. This addresses the need for quantifying and comparing interstitial transport parameters of macromolecules and nanoparticles in vivo for evaluating and optimizing interstitially injected drugs and drug carriers. The model is unique in both approach and capability: using robust theoretical modeling, together with a simple experimental system, it provides an effective means to evaluate small differences in interstitial transport between various types of particles by eliminating experimental differences between animals, injection conditions, and flow characteristics particular to the needle placement and specific anatomy of each mouse tail.
Several key generalizations of interstitial transport phenomena are demonstrated from our results. First, a size exclusion phenomenon apparently dominates differences in solute transport for uncharged dextrans within a molecular mass range of 3-71 kDa. Again, size exclusion refers to the phenomenon where smaller molecules convect at a slower rate than larger molecules, and such observations of macromolecules or plasma proteins through the interstitial space have been exten- ␥i, The mean relative solute velocity ratio (n ϭ 3). Radii (r) were calculated values of the Stokes-Einstein radius, except the nanospheres, which were sized by the manufacturer. Average R 2 values are given for the fits to Eq. 9 (to determine ␥i for each particle). 40k-Dx, 71k-Dx, and 2M-Dx: 40-, 71-, and 2,000-kDa dextran; 3k-An-Dx, anionic 3-kDa dextran; 69k-BSA, bovine serum albumin at 69 kDa. Fig. 4 . Average relative solute velocity ratio, ␥i, and standard deviation for each test particle. 3k-An-Dx, anionic 3-kDa dextran; 40k-Dx, 40-kDa dextran; 69k-BSA, bovine serum albumin at 69 kDa.
sively reported by others (2, 6, 22, 23) . For larger molecules such as 2M-Dx, we observed that mechanical hindrances due to solute interactions with the matrix counteract the size exclusion phenomena and slow convection compared with 71 kD-Dx. Furthermore, the 40-nm nanospheres convected more slowly through the interstitium than all the test molecules and reference molecules. This may be attributed to the fact that the nanospheres are rigid with a fixed radius as opposed to the dextran molecules (whose Stokes-Einstein radii represent the gross approximation of the volume that they may occupy), which are flexible and deformable chains that can easily move through pores and avoid other hindrances.
While size was important, charge and shape were also seen to affect interstitial transport. To examine the effects of charge, we compared anionic dextran (3k-An-Dx) with neutral 3k-Dx. The anionic molecule moved with a higher average velocity through the interstitium than the neutral molecule, suggesting that electrostatic repulsion may serve to reduce the interactions between a negatively charged solute and the ECM, since the latter is also negatively charged (2) .
The albumin served to compare the effects of both size and shape since, although at 69 kDa it is roughly the same molecular mass as the 71k-Dx, it is a folded protein with heterogeneous charge distribution. We found that it convected nearly three times slower than the 71k-Dx (␥ 69k-BSA ϭ 2.4, while ␥ 71k-Dx ϭ 7), and its convection coefficient was similar to that of 40k-Dx (Table 1 ). This suggests that 1) molecular mass does not affect solute transport as much as size and shape, and 2) globular proteins, with their nonuniform charge distribution, may interact more with the ECM than neutral linear molecules, leading to greater mechanical hindrance in convection.
In summary, these experimental studies demonstrate the development, utility, and sensitivity of a model for quantifying convective interstitial transport of injected macromolecules and nanoparticles. It is ideal for comparing and optimizing interstitial transport of different drug delivery vehicles such as polymer nanoparticles, micelles, or antibody-protein conjugates that utilize the interstitium and lymphatics as delivery routes. Furthermore, this model may be employed to characterize the effects of different remodeled tissue matrix on interstitial transport, especially in situations where drug delivery is important, such as in tumors or implants, or in lymphedematous conditions.
APPENDIX
This problem involves the transport of 1) fluid, which moves through the interstitium and can be absorbed into the blood vessels and lymphatics, 2) a smaller solute that may be absorbed into blood and lymphatics, and 3) a larger solute that can be absorbed by lymphatics but not blood vessels. All transport is assumed to be dependent only on x and t. The fluid movement is slowed by uptake into blood or lymphatics, according to the following steady-state mass balance:
where Q l and Q b are the uptake rates into lymphatic and blood vessels (ml ⅐ s Ϫ1 ⅐ ml tissue Ϫ1 ), respectively.
As the transport problem is one-dimensional in the x-direction (i.e., in the axial direction along the length of the tail), the resulting mass balance for solute i moving with this fluid, assuming convective transport dominates molecular diffusion, is:
where Ci is concentration of solute i (mg/ml tissue), ui is convective velocity of i (x-component of u), Di is dispersion (convective) coefficient of i (here we assume convective dispersion dominates over molecular diffusion in the region of measurement, which was verified experimentally), and J i b and J i l are the fluxes of i into the blood and lymphatics, respectively. The solute velocity varies in x and is related to the fluid velocity by a convection coefficient i:
J i b and J i l are described by:
where i b and i l are the solute reflection coefficients for blood and lymphatic uptake, respectively; PSb and PSl are the permeability coefficients multiplied by the surface areas for blood and lymphatic vessels, respectively; and ⌬C i b and ⌬C i l are the change in solute concentration between the interstitium and blood and lymphatic vessels, respectively. We assume that the lymphatics are at least as permeable to solutes as the interstitial space (18) , so that there is no concentration difference between solute in the interstitial space and that in the lymphatics:
This essentially implies that solute transport from the interstitial space into the lymphatics occurs mainly by convection, and that there is no convective partitioning of solute at the lymphatic-interstitial boundary.
Combining Eq. A1 through Eq. A7 (and noting that the term describing convective uptake into the lymphatics balances out with the decrease in overall flow rate due to lymphatic uptake),
Thus lymphatic uptake neither concentrates nor dilutes the solute concentration in the interstitium, as expected, if we assume that the lymphatics are freely permeable to molecules within our size range. Substituting dimensionless variables x ϭ x/L, t ϭ t/, and C i ϭ Ci/Co, where L is the length scale over which our solute convects in time and Co is the maximum (injected) concentration. Assuming C i b is sufficiently low compared with Ci that ⌬C i b Ϸ Ci, we obtain the dimensionless equation:
Thus changes in solute concentration measured in the interstitium can be due to convective transport, convective dispersion, fluid uptake into the blood (which would change interstitial solute concentration only if solute is "held up" or filtered such that interstitial concentration would increase over time), and diffusion into the blood (which would decrease interstitial concentration). The validity of our model rests on the assumption that changes in interstitial solute due to blood uptake of fluid and solute (the terms grouped as "dilution/concentration" in Eq. A9) is small compared with changes due to interstitial convection (the terms grouped "convection" in Eq. A9), and that the actual interstitial solute velocity is approximately equal to the measured velocity of the moving front:
To evaluate the scale of this ratio, we averaged the ui for each solute within the first ϳ0.2 cm from the injection for each experiment, and estimate Q b from Starling's Law:
where Lv is the filtration coefficient, and ⌬P Ϫ ⌬ is the difference in hydrostatic and osmotic pressure, respectively, between the inside and outside of the blood vessel. In skin, L v Х 0.01 ml ⅐ min Ϫ1 ⅐ mmHg Ϫ1 ⅐ 100 g tissue Ϫ1 (10), and ⌬P Ϫ ⌬ is typically ϳ0 -1 mmHg (10), and so during an interstitial infusion, the infusion pressure dominates the driving force for convective fluid uptake into the blood. In our case, the infusion pressure is 33 mmHg but decays exponentially, and baseline tissue pressure in the tail skin is ϳ9 mmHg (18) . Therefore, the maximum interstitial pressure is 24 mmHg at x ϭ 0, and the maximum convective flux from tissue into the blood vessels would be Q b ϭ 4 ϫ 10 Ϫ5 ml ⅐ s Ϫ1 ⅐ g tissue Ϫ1 . We estimated from the literature values for PS (9) and b (26), according to molecular mass or approximate Stokes-Einstein radius. For u i, we assume that this is equal to our measured solute velocity, according to the diffuse moving front of the solute (see Fig. 1 , B and C), which is to be verified here a posteriori (i.e., if convection does indeed dominate interstitial dilution/concentration due to blood uptake). Thus values of maximum solute velocities were taken at x ϭ 0 and averaged for each solute from plots of x vs. t (i.e., Fig. 3 ). To estimate L, approximate distances at which dC/dx 3 0 were found to be, on average, 0.5 cm for the solutes. We do not know i, since we can only calculate velocity ratios from our measurements (i.e., test solute velocity/reference solute velocity) and do not directly measure the fluid velocity v. However, if we assume that r for the tracer is close to 1 since it is small, or that its limit is 1, then i ϭ ␥i (see Eq. 4). Therefore, values for i were taken from Table 1 for this scaling exercise.
As shown in Table 2 , the absolute values of the estimated ratios of interstitial convection to dilution/concentration due to uptake into the blood for solute (convection/dilution from Eq. A10) are always much greater than 1, validating a posteriori the measurement of moving solute front as approximately equal to the solute velocity. Parameter values in Table 2 were obtained or calculated from Refs. 9, 10, 23, and 24. 
